ArticlePulmonary circulation
Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies.
Article in Pulmonary circulation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- International Liver Transplantation Society practice guideline update on portopulmonary hypertension.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2026Guideline
- Clinical aspects encountered in patients with portopulmonary hypertension.Medicine and pharmacy reports · 2025Review
- Rare but serious: pulmonary vascular disease around the world.JHLT open · 2025Review
- Survival Outcomes and Impact of Targeted PAH Therapy in Portopulmonary Hypertension in the PVRI GoDeep Meta-Registry.Pulmonary circulation · 2025Article
- Making Living-donor Liver Transplantation a Viable Option for Patients With Portopulmonary Hypertension.Transplantation direct · 2024Article
- Clinical outcomes of upfront combination therapy for portopulmonary hypertension.International journal of cardiology. Cardiovascular risk and prevention · 2024Article
- Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies.Pulmonary therapy · 2024Article
- When Pulmonary Arterial Hypertension may be Associated with Portal Hypertension: A Case Report of Two Different Hepatic Disorders in One Patient with Pulmonary Hypertension.Current cardiology reviews · 2024Review
- [Pulmonary Complications in Patients with Liver Cirrhosis].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2023Review
- Macitentan treatment of portopulmonary hypertension with hepatopulmonary syndrome: a case report and literature review.ESC heart failure · 2023Review
- Portopulmonary Hypertension: An Updated Review.Transplantation direct · 2023Review
- Portopulmonary hypertension: Current developments and future perspectives.Liver research (Beijing, China) · 2022Review
- Evaluating Riociguat in the Treatment of Pulmonary Arterial Hypertension: A Real-World Perspective.Vascular health and risk management · 2022Review
- Hepatopulmonary Syndrome and Portopulmonary Hypertension: Current Status and Implications for Liver Transplantation.Current hepatology reports · 2020Article
- Portopulmonary Hypertension: From Bench to Bedside.Frontiers in medicine · 2020Review
- Pulmonary arterial hypertension populations of special interest: portopulmonary hypertension and pulmonary arterial hypertension associated with congenital heart disease.European heart journal supplements : journal of the European Society of Cardiology · 2019Article
- Treatment Barriers in Portopulmonary Hypertension.Hepatology (Baltimore, Md.) · 2019Review
- Pulmonary manifestations of chronic liver disease: a comprehensive review.Annals of gastroenterologyReview
- Practical management of riociguat in patients with pulmonary arterial hypertension.Therapeutic advances in respiratory diseaseReview
- Pulmonary Assessment of the Liver Transplant Recipient.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In patients with portopulmonary hypertension (n = 13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC improvements were sustained over two years in the open-label extension, PATENT-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.